Protein Quality Control Systems in Neurodegeneration—Chaperones, Cytoskeleton, and the Pathogenic Transition of Tau
Authors:
- 1 January 2026
- journal article
- review article
- Published by Springer Nature in Molecular Neurobiology
- Vol. 63 (1) , 1007
Abstract
No abstract availableKeywords
Funding Information
- Department of Biotechnology, Ministry of Science and Technology, India (BT/PR52508/BMS/85/200/2024)
This publication has 254 references indexed in Scilit:
- Tau Protein and Tauopathies: Exploring Tau Protein–Protein and Microtubule Interactions, Cross‐Interactions and Therapeutic StrategiesChemMedChem, 2024
- A small‐molecule microtubule‐stabilizing agent safely reduces Aβ plaque and tau pathology in transgenic mouse models of Alzheimer's diseaseAlzheimer's & Dementia, 2024
- Tau, microtubule dynamics, and axonal transport: New paradigms for neurodegenerative diseaseBioEssays, 2023
- Heat shock proteins: Biological functions, pathological roles, and therapeutic opportunitiesMedcomm, 2022
- Reduction in Aha1 chaperone preserves hippocampal neurons and prevents tau‐related pathology in rTg4510 tau transgenic miceAlzheimer's & Dementia, 2021
- Longitudinal evaluation of Tau‐P301L transgenic mice reveals no cognitive impairments at 17 months of ageBrain and Behavior, 2017
- The cytoskeleton in neurodegenerative diseasesThe Journal of Pathology, 2004
- Transgenic zebrafish model of neurodegenerationJournal of Neuroscience Research, 2002
- Tau and tau reporters disrupt central projections of sensory neurons inDrosophilaJournal of Comparative Neurology, 2000
- Phosphorylation determines two distinct species of tau in the central nervous systemCell Motility, 1987